Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The investigators propose to conduct a phase 2 randomised (1:1) double-blind
placebo-controlled trial of the dolutegravir-lamivudine-tenofovir fixed dose combination
tablet daily with an additional 50 mg dose of dolutegravir/matching placebo taken 12 hours
later in ART-naïve or fisrt-line interrupted HIV-infected patients on rifampicin-based
anti-tuberculosis therapy. The hypothesis is that virologic outcomes with standard dose
dolutegravir-based ART will be acceptable in patients on rifampicin-based anti-tuberculosis
therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cape Town
Collaborators:
Medecins Sans Frontieres, Netherlands Wellcome Trust